natural gip and glp-1 receptor agonists next-generation metabolic hormone therapies in chronic kidney disease Glp-1: The Key to Weight

Tirzepatide at the highest dose produced even more dramatic results, with average weight loss reaching 20.2% in the SURMOUNT-5 trial

Human trials are small and inconsistent Robust human clinical trials on injectable peptides for knee healing are limited

October 9, 2024 - Branding Update (October 2024) As a reminder, in July of 2023 we launched Jefferson Health Plans as our official marketing name for certain Health Partners Plans, Inc

Role of renal tubular programed cell death in diabetic kidney disease

60 years of Cimicifuga racemosa medicinal products : Clinical research milestones, current study findings and current development